Actively Recruiting
Phase 3 Trial of Suzetrigine Tablets for Pain in Adults with Diabetic Peripheral Neuropathy
Led by Vertex Pharmaceuticals Incorporated · Updated on 2026-07-20
734
Participants Needed
75
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the efficacy, safety, and tolerability of Suzetrigine in adults experiencing pain related to diabetic peripheral neuropathy DPN. The study focuses on participants with type 1 or type 2 diabetes who have had bilateral lower extremity pain from DPN for at least one year, seeking to understand how Suzetrigine impacts their pain levels compared to placebo. Participants will be randomly assigned to one of two groups those receiving Suzetrigine tablets and those receiving a matching placebo, both taken orally. The study uses a parallel design and is conducted in a double-blind manner to assess the treatment effects over a 12-week period. During the study, participants will have their daily pain intensity measured using the Numeric Pain Rating Scale NPRS and physical health status assessed via the SF-36 questionnaire. Researchers will monitor changes from baseline to week 12 to evaluate the treatment impact. The study spans from screening through 12 weeks of treatment, with safety and tolerability closely observed throughout this period.
CONDITIONS
Brief Title
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Research Team
M
Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
